Short answer
Tvardi Therapeutics, Inc. (TVRD) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$6M
- +55.7% YoY · −992.3% QoQ
- EPS (diluted)
- −$0.46
- −109.1% YoY · −139.0% QoQ
Source: XBRL data from the Tvardi Therapeutics, Inc. (TVRD) Q3 2025 10-Q on SEC EDGAR. USD.
Tvardi Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical trial data risk: Phase 2 trial of TTI-101 in IPF failed primary goals as of October 2025, triggering additional analyses and uncertain next steps
- Most materially updated financial risk: Cash and equivalents $21.4M, short-term investments $15.0M as of Sept 30, 2025, significant doubt about going concern status
- Regulatory risk: FDA orphan drug and Fast Track designations for TTI-101 provide no assurance of faster approval or market exclusivity
- Operational risk: Reliance on third-party contractors for clinical trials poses risk of delays or non-compliance affecting development timelines
- Financial risk: No committed external funding; additional capital needed amid volatile markets; failure to raise funds may require project delays or cutbacks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tvardi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.